Janssen Trims Two Claims From Remicade Biosimilar Battle
Janssen Biotech Inc. voluntarily agreed to dismiss two of its patent infringement claims against Celltrion Inc. in Massachusetts federal court on Monday, trimming the lawsuit it launched to delay Celltrion's proposed...To view the full article, register now.
Already a subscriber? Click here to view full article